Thus, these findings demonstrated that in myeloid cells, S100A8/A9 induces the transition from adaptive hypertrophy to HF, suggesting that targeting S100A8/A9 is a new therapeutic strategy for the treatment of this disease. This evidence concerns the gene IGKV1D-22 and hydrops fetalis.